NYSE:GSK - GlaxoSmithKline Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $37.61 -0.33 (-0.87 %) (As of 12/16/2018 04:00 PM ET)Previous Close$37.61Today's Range$37.40 - $37.675052-Week Range$34.83 - $42.36Volume4.22 million shsAverage Volume3.55 million shsMarket Capitalization$93.27 billionP/E Ratio13.06Dividend Yield5.17%Beta0.81 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; and a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom. Receive GSK News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:GSK Previous Symbol CUSIPN/A Webwww.gsk.com Phone44-20-8047-5000 Debt Debt-to-Equity Ratio6.66 Current Ratio0.95 Quick Ratio0.63 Price-To-Earnings Trailing P/E Ratio13.06 Forward P/E Ratio12.75 P/E Growth2.54 Sales & Book Value Annual Sales$38.89 billion Price / Sales2.40 Cash Flow$3.8378 per share Price / Cash Flow9.80 Book Value$1.81 per share Price / Book20.78 Profitability EPS (Most Recent Fiscal Year)$2.88 Net Income$1.97 billion Net Margins5.78% Return on Equity164.99% Return on Assets9.96% Miscellaneous Employees99,349 Outstanding Shares2,479,930,000Market Cap$93.27 billion OptionableOptionable GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions What is GlaxoSmithKline's stock symbol? GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK." How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline? GlaxoSmithKline declared a quarterly dividend on Thursday, November 1st. Stockholders of record on Friday, November 16th will be given a dividend of $0.486 per share on Thursday, January 10th. This represents a $1.94 annualized dividend and a dividend yield of 5.17%. The ex-dividend date is Thursday, November 15th. This is a positive change from GlaxoSmithKline's previous quarterly dividend of $0.46. View GlaxoSmithKline's Dividend History. How were GlaxoSmithKline's earnings last quarter? GlaxoSmithKline plc (NYSE:GSK) released its quarterly earnings results on Wednesday, October, 31st. The pharmaceutical company reported $0.83 earnings per share for the quarter, missing analysts' consensus estimates of $0.86 by $0.03. The pharmaceutical company had revenue of $9.41 billion for the quarter, compared to analyst estimates of $10.55 billion. GlaxoSmithKline had a net margin of 5.78% and a return on equity of 164.99%. View GlaxoSmithKline's Earnings History. When is GlaxoSmithKline's next earnings date? GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for GlaxoSmithKline. What price target have analysts set for GSK? 19 brokerages have issued 12 month price objectives for GlaxoSmithKline's stock. Their predictions range from $36.95 to $47.00. On average, they anticipate GlaxoSmithKline's share price to reach $41.1583 in the next year. This suggests a possible upside of 9.4% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline. What is the consensus analysts' recommendation for GlaxoSmithKline? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 1 sell rating, 11 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline. Has GlaxoSmithKline been receiving favorable news coverage? Headlines about GSK stock have been trending somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GlaxoSmithKline earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned press coverage about the pharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. Who are some of GlaxoSmithKline's key competitors? Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG) and Allergan (AGN). Who are GlaxoSmithKline's key executives? GlaxoSmithKline's management team includes the folowing people: Ms. Emma Walmsley, CEO & Director (Age 48)Mr. Simon P. Dingemans, CFO & Exec. Director (Age 54)Mr. Jack Bailey, Pres of US PharmaceuticalsMs. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 55) Who are GlaxoSmithKline's major shareholders? GlaxoSmithKline's stock is owned by a number of of institutional and retail investors. Top institutional investors include Dodge & Cox (1.94%), FMR LLC (0.77%), Fisher Asset Management LLC (0.56%), Renaissance Technologies LLC (0.41%), Morgan Stanley (0.17%) and Federated Investors Inc. PA (0.16%). View Institutional Ownership Trends for GlaxoSmithKline. Which major investors are selling GlaxoSmithKline stock? GSK stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Federated Investors Inc. PA, Primecap Management Co. CA, Envestnet Asset Management Inc., BlackRock Inc., Bruderman Asset Management LLC, Dodge & Cox and NWQ Investment Management Company LLC. View Insider Buying and Selling for GlaxoSmithKline. Which major investors are buying GlaxoSmithKline stock? GSK stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Eaton Vance Management, Morgan Stanley, Sio Capital Management LLC, FMR LLC, Diamond Hill Capital Management Inc. and Fisher Asset Management LLC. View Insider Buying and Selling for GlaxoSmithKline. How do I buy shares of GlaxoSmithKline? Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is GlaxoSmithKline's stock price today? One share of GSK stock can currently be purchased for approximately $37.61. How big of a company is GlaxoSmithKline? GlaxoSmithKline has a market capitalization of $93.27 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,349 workers across the globe. What is GlaxoSmithKline's official website? The official website for GlaxoSmithKline is http://www.gsk.com. How can I contact GlaxoSmithKline? GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected] MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)Community Ranking: 1.8 out of 5 ()Outperform Votes: 505 (Thanks for Voting!)Underperform Votes: 867 (Thanks for Voting!)Total Votes: 1,372MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: What is Compound Annual Growth Rate (CAGR)?